# ACCESS Newswire Inc.: financial statements, quarterly

ACCS · NYSE · CIK 843006 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/accs.md) · [Financials](/companies/accs/financials.md) · [Filings](/companies/accs/filings.md) · [Insiders](/companies/accs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/accs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.6](/filings/0001654954-24-013940.md) | [(1.3) d](/filings/0000843006-25-000012.md) | [5.6](/filings/0000843006-25-000025.md) | [6.0](/filings/0000843006-25-000041.md) | [5.6](/filings/0001683168-25-008214.md) | [5.8 d](/filings/0001683168-26-002018.md) | [5.5](/filings/0001683168-26-003723.md) | [5.6](/filings/0001683168-26-006204.md) | [5.7](/filings/0001683168-25-008214.md) | [5.8 d](/filings/0001683168-26-002018.md) | [5.3](/filings/0001683168-26-003723.md) | [5.6](/filings/0001683168-26-006204.md) |
| Cost of revenue | $m | [1.8](/filings/0001654954-24-013940.md) | [(0.4) d](/filings/0000843006-25-000012.md) | [1.4](/filings/0000843006-25-000025.md) | [1.4](/filings/0000843006-25-000041.md) | [1.4](/filings/0001683168-25-008214.md) | [1.4 d](/filings/0001683168-26-002018.md) | [1.2](/filings/0001683168-26-003723.md) | [1.3](/filings/0001683168-26-006204.md) | [1.5](/filings/0001683168-25-008214.md) | [1.3 d](/filings/0001683168-26-002018.md) | [1.4](/filings/0001683168-26-003723.md) | [1.5](/filings/0001683168-26-006204.md) |
| Gross profit | $m | [5.8](/filings/0001654954-24-013940.md) | [(1.0) d](/filings/0000843006-25-000012.md) | [4.2](/filings/0000843006-25-000025.md) | [4.6](/filings/0000843006-25-000041.md) | [4.2](/filings/0001683168-25-008214.md) | [4.4 d](/filings/0001683168-26-002018.md) | [4.3](/filings/0001683168-26-003723.md) | [4.3](/filings/0001683168-26-006204.md) | [4.3](/filings/0001683168-25-008214.md) | [4.5 d](/filings/0001683168-26-002018.md) | [4.0](/filings/0001683168-26-003723.md) | [4.1](/filings/0001683168-26-006204.md) |
| Research and development | $m | [0.6](/filings/0001654954-24-013940.md) | [0.7 d](/filings/0000843006-25-000012.md) | [0.7](/filings/0000843006-25-000025.md) | [0.7](/filings/0000843006-25-000041.md) | [0.7](/filings/0001683168-25-008214.md) | [0.8 d](/filings/0001683168-26-002018.md) | [0.7](/filings/0001683168-26-003723.md) | [0.7](/filings/0001683168-26-006204.md) | [0.7](/filings/0001683168-25-008214.md) | [0.6 d](/filings/0001683168-26-002018.md) | [0.6](/filings/0001683168-26-003723.md) | [0.5](/filings/0001683168-26-006204.md) |
| Operating income | $m | [0.6](/filings/0001654954-24-013940.md) | [(5.7) d](/filings/0000843006-25-000012.md) | [(0.9)](/filings/0000843006-25-000025.md) | [(0.5)](/filings/0000843006-25-000041.md) | [(0.6)](/filings/0001683168-25-008214.md) | [(14.3) d](/filings/0001683168-26-002018.md) | [(0.7)](/filings/0001683168-26-003723.md) | [(0.2)](/filings/0001683168-26-006204.md) | [(0.2)](/filings/0001683168-25-008214.md) | [(0.8) d](/filings/0001683168-26-002018.md) | [(0.7)](/filings/0001683168-26-003723.md) | [(0.3)](/filings/0001683168-26-006204.md) |
| Interest expense | $m | not reported | not reported | [0.3](/filings/0000843006-25-000025.md) | not reported | not reported | not reported | [0.2](/filings/0000843006-25-000025.md) | [(0.0)](/filings/0001683168-26-006204.md) | not reported | not reported | [0.0](/filings/0001683168-26-003723.md) | [0.0](/filings/0001683168-26-006204.md) |
| Income tax | $m | [0.2](/filings/0001654954-24-013940.md) | [(1.6) d](/filings/0000843006-25-000012.md) | [(0.2)](/filings/0000843006-25-000025.md) | [(0.1)](/filings/0000843006-25-000041.md) | [(0.3)](/filings/0001683168-25-008214.md) | [(3.4) d](/filings/0001683168-26-002018.md) | [(0.2)](/filings/0001683168-26-003723.md) | [(0.0)](/filings/0001683168-26-006204.md) | [0.1](/filings/0001683168-25-008214.md) | [(0.3) d](/filings/0001683168-26-002018.md) | [(0.1)](/filings/0001683168-26-003723.md) | [0.1](/filings/0001683168-26-006204.md) |
| Net income | $m | [0.3](/filings/0001654954-24-013940.md) | [(0.7) d](/filings/0000843006-25-000012.md) | [(0.1)](/filings/0001683168-25-008214.md) | [0.0](/filings/0001683168-25-008214.md) | [(0.5)](/filings/0001683168-25-008214.md) | [(10.2) d](/filings/0001683168-26-002018.md) | [5.4](/filings/0001683168-26-006204.md) | [(0.5)](/filings/0001683168-26-006204.md) | [(0.0)](/filings/0001683168-25-008214.md) | [(0.6) d](/filings/0001683168-26-002018.md) | [(0.6)](/filings/0001683168-26-006204.md) | [(0.5)](/filings/0001683168-26-006204.md) |
| Diluted EPS | $ per share | [0.07](/filings/0001654954-24-013940.md) | not reported | [(0.04)](/filings/0000843006-25-000025.md) | [0.00](/filings/0000843006-25-000041.md) | [(0.12)](/filings/0001683168-25-008214.md) | not reported | [1.40](/filings/0001683168-26-003723.md) | [(0.12)](/filings/0001683168-26-006204.md) | [(0.01)](/filings/0001683168-25-008214.md) | not reported | [(0.16)](/filings/0001683168-26-003723.md) | [(0.12)](/filings/0001683168-26-006204.md) |
| Basic EPS | $ per share | [0.07](/filings/0001654954-24-013940.md) | not reported | [(0.04)](/filings/0000843006-25-000025.md) | [0.00](/filings/0000843006-25-000041.md) | [(0.12)](/filings/0001683168-25-008214.md) | not reported | [1.40](/filings/0001683168-26-003723.md) | [(0.12)](/filings/0001683168-26-006204.md) | [(0.01)](/filings/0001683168-25-008214.md) | not reported | [(0.16)](/filings/0001683168-26-003723.md) | [(0.12)](/filings/0001683168-26-006204.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [4.1](/filings/0001683168-26-002018.md) | not reported | [2.2](/filings/0000843006-25-000041.md) | [3.3](/filings/0001683168-25-008214.md) | [3.0](/filings/0001683168-26-006204.md) | [3.5](/filings/0001683168-26-003723.md) | [3.0](/filings/0001683168-26-006204.md) |
| Current assets | $m | [10.8](/filings/0001654954-23-014030.md) | [11.5](/filings/0000843006-25-000012.md) | [11.1](/filings/0001654954-24-005891.md) | [10.2](/filings/0001654954-24-010184.md) | [10.0](/filings/0001654954-24-013940.md) | [10.0](/filings/0001683168-26-002018.md) | [10.1](/filings/0000843006-25-000025.md) | [9.7](/filings/0000843006-25-000041.md) | [9.0](/filings/0001683168-25-008214.md) | [8.4](/filings/0001683168-26-006204.md) | [8.7](/filings/0001683168-26-003723.md) | [7.6](/filings/0001683168-26-006204.md) |
| Total assets | $m | [65.5](/filings/0001654954-23-014030.md) | [65.2](/filings/0000843006-25-000012.md) | [64.4](/filings/0001654954-24-005891.md) | [62.8](/filings/0001654954-24-010184.md) | [61.7](/filings/0001654954-24-013940.md) | [50.6](/filings/0001683168-26-002018.md) | [47.3](/filings/0000843006-25-000025.md) | [45.6](/filings/0000843006-25-000041.md) | [44.1](/filings/0001683168-25-008214.md) | [42.0](/filings/0001683168-26-006204.md) | [41.6](/filings/0001683168-26-003723.md) | [40.0](/filings/0001683168-26-006204.md) |
| Current liabilities | $m | [11.7](/filings/0001654954-23-014030.md) | [12.7](/filings/0000843006-25-000012.md) | [13.2](/filings/0001654954-24-005891.md) | [12.6](/filings/0001654954-24-010184.md) | [12.6](/filings/0001654954-24-013940.md) | [12.8](/filings/0001683168-26-002018.md) | [13.5](/filings/0000843006-25-000025.md) | [12.2](/filings/0000843006-25-000041.md) | [10.8](/filings/0001683168-25-008214.md) | [9.5](/filings/0001683168-26-006204.md) | [9.9](/filings/0001683168-26-003723.md) | [9.3](/filings/0001683168-26-006204.md) |
| Total liabilities | $m | [29.7](/filings/0001654954-23-014030.md) | [29.7](/filings/0000843006-25-000012.md) | [29.2](/filings/0001654954-24-005891.md) | [27.4](/filings/0001654954-24-010184.md) | [26.5](/filings/0001654954-24-013940.md) | [25.4](/filings/0001683168-26-002018.md) | [16.4](/filings/0000843006-25-000025.md) | [14.9](/filings/0000843006-25-000041.md) | [13.3](/filings/0001683168-25-008214.md) | [11.6](/filings/0001683168-26-006204.md) | [11.7](/filings/0001683168-26-003723.md) | [10.8](/filings/0001683168-26-006204.md) |
| Long-term debt | $m | [16.9](/filings/0001654954-23-014030.md) | [15.9](/filings/0000843006-25-000012.md) | [14.9](/filings/0001654954-24-005891.md) | [13.9](/filings/0001654954-24-010184.md) | [12.9](/filings/0001654954-24-013940.md) | [11.9](/filings/0001683168-26-002018.md) | [2.3](/filings/0000843006-25-000025.md) | [2.1](/filings/0000843006-25-000041.md) | [1.9](/filings/0001683168-25-008214.md) | [1.7](/filings/0001683168-26-006204.md) | [1.5](/filings/0001683168-26-003723.md) | [1.3](/filings/0001683168-26-006204.md) |
| Current portion of debt | $m | [3.0](/filings/0001654954-23-014030.md) | [4.0](/filings/0000843006-25-000012.md) | [4.0](/filings/0001654954-24-005891.md) | [4.0](/filings/0001654954-24-010184.md) | [3.7](/filings/0001654954-24-013940.md) | [4.0](/filings/0001683168-26-002018.md) | [0.9](/filings/0000843006-25-000025.md) | [0.9](/filings/0000843006-25-000041.md) | [0.9](/filings/0001683168-25-008214.md) | [0.9](/filings/0001683168-26-006204.md) | [0.9](/filings/0001683168-26-003723.md) | [0.9](/filings/0001683168-26-006204.md) |
| Shareholders' equity | $m | [35.8](/filings/0001654954-24-013940.md) | [35.4](/filings/0001683168-26-002018.md) | [35.2](/filings/0001683168-25-008214.md) | [35.4](/filings/0001683168-25-008214.md) | [35.3](/filings/0001683168-25-008214.md) | [25.2](/filings/0001683168-26-006204.md) | [30.9](/filings/0001683168-26-006204.md) | [30.7](/filings/0001683168-26-006204.md) | [30.8](/filings/0001683168-25-008214.md) | [30.3](/filings/0001683168-26-006204.md) | [29.9](/filings/0001683168-26-006204.md) | [29.3](/filings/0001683168-26-006204.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [287 d](/filings/0001654954-24-013940.md) | [770 d](/filings/0000843006-25-000012.md) | [986](/filings/0000843006-25-000025.md) | [(190) d](/filings/0000843006-25-000041.md) | [1,498 d](/filings/0001683168-25-008214.md) | [866 d](/filings/0001683168-26-002018.md) | [747](/filings/0001683168-26-003723.md) | [135 d](/filings/0001683168-26-006204.md) | [(582) d](/filings/0001683168-25-008214.md) | [258 d](/filings/0001683168-26-002018.md) | [871](/filings/0001683168-26-003723.md) | [173 d](/filings/0001683168-26-006204.md) |
| Capital expenditure | $k | [15.0 d](/filings/0001654954-24-013940.md) | [(1.0) d](/filings/0000843006-25-000012.md) | [16.0](/filings/0000843006-25-000025.md) | [0.0 d](/filings/0000843006-25-000041.md) | [3.0 d](/filings/0001683168-25-008214.md) | [0.0 d](/filings/0001683168-26-002018.md) | [12.0](/filings/0001683168-26-003723.md) | [0.0 d](/filings/0001683168-26-006204.md) | [8.0 d](/filings/0001683168-25-008214.md) | [0.0 d](/filings/0001683168-26-002018.md) | [9.0](/filings/0001683168-26-003723.md) | [13.0 d](/filings/0001683168-26-006204.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | [0.0 d](/filings/0001654954-23-014030.md) | [0.0 d](/filings/0001654954-24-002824.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3.6](/filings/0001654954-23-014030.md) | [3.8](/filings/0001654954-24-005891.md) | [3,808](/filings/0001654954-24-010184.md) | [3.8](/filings/0001654954-24-013940.md) | [3.8](/filings/0000843006-25-000025.md) | [3,823](/filings/0000843006-25-000041.md) | [3.8](/filings/0001683168-25-008214.md) | [3,843](/filings/0001683168-26-003723.md) | [3,857](/filings/0001683168-26-006204.md) | [3.9](/filings/0001683168-25-008214.md) | [3,860](/filings/0001683168-26-003723.md) | [3,862](/filings/0001683168-26-006204.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,827,304 at 2026-08-10, from the cover of the [10-Q filed 2026-08-11](/filings/0001683168-26-006204.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.